Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (55)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van den Bent, M. J.
Right arrow Articles by Baron, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Bent, M. J.
Right arrow Articles by Baron, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:599-602, 2003
© 2003 European Society for Medical Oncology

Original Paper

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972

M. J. van den Bent1,+, O. Chinot2, W. Boogerd3, J. Bravo Marques4, M. J. B. Taphoorn5, J. M. Kros6, C. C. D. van der Rijt7, C. J. Vecht8, N. De Beule9 and B. Baron9

Departments of 1 Neuro-Oncology, 6 Pathology and 7 Medical Oncology, University Hospital Rotterdam/Rotterdam Cancer Center, The Netherlands; 2 CHU de la Timone, Marseilles, France; 3 Netherlands Cancer Institute, Amsterdam, The Netherlands; 4 IPO Francisco Gentil, Lisbon, Portugal; 5 Department of Neurology, University Medical Center Utrecht, The Netherlands; 8 Department of Neurology, Medical Center Haaglanden/Westeinde, The Hague, The Netherlands; 9 European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium

Received 5 July 2002; revised 21 October 2002; accepted 21 November 2002

Background:

Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy.

Patients and methods:

In a prospective non-randomized multicenter phase II trial patients were treated with TMZ 150 mg/m2 on days 1–5 in cycles of 28 days for 12 cycles. Eligible patients had a recurrence after prior PCV chemotherapy, with measurable and enhancing disease as shown by magnetic resonance imaging. Pathology and all responses were centrally reviewed.

Results:

Thirty-two eligible patients were included. In four patients the pathology review did not confirm the presence of an OD or OA. Twelve of 24 patients [50%, 95% confidence interval (CI) 29% to 71%] evaluable for response to first-line PCV chemotherapy had responded to PCV. Temozolomide was in general well tolerated; the most frequent side-effects were hematological. One patient discontinued treatment due to toxicity. In seven of 28 patients (25%, 95% CI 11% to 45%) with histologically confirmed OD an objective response to TMZ was observed. Median time to progression for responding patients was 8.0 months. After 6 and 12 months from the start of treatment, 29% and 11% of patients, respectively, were still free from progression.

Conclusions:

TMZ may be regarded as the preferred second-line treatment in OD after failure of PCV chemotherapy. Further studies on TMZ in OD are indicated.

Key words: chemotherapy, oligoastrocytoma, oligodendroglioma, recurrent, second line, temozolomide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, et al.
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
Neurology, May 5, 2009; 72(18): 1601 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. E. C. Bromberg and M. J. van den Bent
Oligodendrogliomas: Molecular Biology and Treatment
Oncologist, February 1, 2009; 14(2): 155 - 163.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncologyHome page
L. E. Abrey, D. N. Louis, N. Paleologos, A. B. Lassman, J. J. Raizer, W. Mason, J. Finlay, D. R. MacDonald, L. M. DeAngelis, J. G. Cairncross, et al.
Survey of treatment recommendations for anaplastic oligodendroglioma
Neuro Oncology, July 1, 2007; 9(3): 314 - 318.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. F. Lang and M. R. Gilbert
Diffusely Infiltrative Low-Grade Gliomas in Adults
J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
J. Clin. Oncol., March 10, 2006; 24(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
K. K. Koeller and E. J. Rushing
From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation
RadioGraphics, November 1, 2005; 25(6): 1669 - 1688.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. H.J.M. Triebels, M. J.B. Taphoorn, A. A. Brandes, J. Menten, M. Frenay, A. Tosoni, J. M. Kros, E. B.-t. Stege, R. H. Enting, A. Allgeier, et al.
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas
Neurology, September 14, 2004; 63(5): 904 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Vera, L. Djafari, S. Faivre, J.-S. Guillamo, K. Djazouli, M. Osorio, F. Parker, C. Cioloca, B. Abdulkarim, J.-P. Armand, et al.
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors
Ann. Onc., January 1, 2004; 15(1): 161 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Pace, A. Vidiri, E. Galie, M. Carosi, S. Telera, A. M. Cianciulli, P. Canalini, D. Giannarelli, B. Jandolo, and C. M. Carapella
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response
Ann. Onc., December 1, 2003; 14(12): 1722 - 1726.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M.J. van den Bent, M.J.B. Taphoorn, A.A. Brandes, J. Menten, R. Stupp, M. Frenay, O. Chinot, J.M. Kros, C.C.D. van der Rijt, Ch.J. Vecht, et al.
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
J. Clin. Oncol., July 1, 2003; 21(13): 2525 - 2528.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.